Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00694707 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 732
- Enrollment target
- 20
- Study locations
NCT00694707 is a Phase 2 study of Schizophrenia that has completed, run by Forest Laboratories. The registered enrollment target is 732 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (237% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT00694707, a Phase 2 study of Schizophrenia, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 732 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG Cariprazine
Study Locations (20)
California
- Forest Investigative Site - Costa Mesa
- Forest Investigative Site - Long Beach
- Forest Investigative Site - Oceanside
- Forest Investigative Site - Paramount
- Forest Investigative Site - Riverside
Texas
- Forest Investigative Site - Houston
- Forest Investigative Site - Houston
- Forest Investigative Site - Irving
Florida
- Forest Investigative Site - Bradenton
- Forest Investigative Site - Kissimmee
District of Columbia
- Forest Investigative Site - Washington D.C.
Louisiana
- Forest Investigative Site - Lake Charles
Maryland
- Forest Investigative Site - Baltimore
Mississippi
- Forest Investigative Site - Flowood
Missouri
- Forest Investigative Site - Bridgeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2008-06-30 |
| Est. Completion | 2009-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00694707
The ClinicalTrials.gov registry entry for NCT00694707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 732 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (237% higher). The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00694707 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT00694707 about?
NCT00694707 is a clinical study titled "Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia". This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
What is the current status of trial NCT00694707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 732 participants. The study started on 2008-06-30. Estimated completion is 2009-08-31.
What conditions does trial NCT00694707 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00694707?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), Cariprazine (DRUG).
Who is sponsoring clinical trial NCT00694707?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00694707 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.